Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.96 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.67 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.67 |
| ▸ | RAB9A | P51151 | 2/20 | 0.67 |
| ▸ | HTT | P42858 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.64 |
| ▸ | PDE5A | O76074 | 1/20 | 0.60 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | STAT3 | P40763 | 1/20 | 0.52 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10343392 | 0.98 | MEN1 (1.00) | MEN1KMT2ARXFP1RAB9AHTT | |
| SCHEMBL1920963 | 0.92 | MEN1 (0.82) | MEN1KMT2ARXFP1RAB9AHTT | |
| SCHEMBL1651778 | 0.91 | MEN1 (0.80) | MEN1KMT2ARXFP1RAB9AHTT | |
| SCHEMBL1604254 | 0.91 | MEN1 (0.80) | MEN1KMT2ARXFP1RAB9AHTT | |
| SCHEMBL12734237 | 0.91 | MEN1 (0.80) | MEN1KMT2ARXFP1RAB9AHTT | |
| SCHEMBL1651331 | 0.90 | MEN1 (0.79) | MEN1KMT2ARXFP1RAB9AHTT | |
| SCHEMBL1920737 | 0.90 | MEN1 (0.78) | MEN1KMT2ARXFP1RAB9AHTT | |
| SCHEMBL1604266 | 0.89 | MEN1 (0.77) | MEN1KMT2ARXFP1RAB9AHTT | |
| SCHEMBL1652468 | 0.89 | MEN1 (0.76) | MEN1KMT2ARXFP1RAB9AHTT | |
| SCHEMBL1651523 | 0.89 | MEN1 (0.76) | MEN1KMT2ARXFP1RAB9AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110082157-A1 | Piperidinylamino-Thieno [2,3-D] Pyrimidine Compounds | TROVIS PHARMACEUTICALS, LLC | 2011-04-07 | — | — | US | disclosed |
| US-20110082157-A1 | Piperidinylamino-Thieno [2,3-D] Pyrimidine Compounds | TROVIS PHARMACEUTICALS, LLC | 2011-04-07 | — | — | US | disclosed |
| US-20110082157-A1 | Piperidinylamino-Thieno [2,3-D] Pyrimidine Compounds | TROVIS PHARMACEUTICALS, LLC | 2011-04-07 | — | — | US | disclosed |
| US-20100280050-A1 | Piperidinylamino-Thieno[2,3-D] Pyrimidine Compounds for Treating Fibrosis | PGXHEALTH, LLC | 2010-11-04 | — | — | US | disclosed |
| US-20100280050-A1 | Piperidinylamino-Thieno[2,3-D] Pyrimidine Compounds for Treating Fibrosis | PGXHEALTH, LLC | 2010-11-04 | — | — | US | disclosed |
| EP-1797099-B1 | PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS | EPIX DELAWARE INC (US) | 2010-08-11 | — | — | EP | disclosed |
| US-20100113485-A1 | Piperidinylamino-thieno[2,3-D] Pyrimidine Compounds | TROVIS PHARMACEUTICALS, LLC | 2010-05-06 | — | — | US | disclosed |
| US-7612078-B2 | Piperidinylamino-thieno[2,3-D] pyrimidine compounds | EPIX DELAWARE, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-7612078-B2 | Piperidinylamino-thieno[2,3-D] pyrimidine compounds | EPIX DELAWARE, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-7612078-B2 | Piperidinylamino-thieno[2,3-D] pyrimidine compounds | EPIX DELAWARE, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| WO-2009032885-A2 | PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS FOR TREATING FIBROSIS | EPIX DELAWARE, INC. (US) | 2009-03-12 | — | — | WO | disclosed |
| US-20050222176-A1 | Piperidinylamino-thieno[2,3-D] pyrimidine compounds | TROVIS PHARMACEUTICALS, LLC | 2005-10-06 | — | — | US | disclosed |
| US-20050222175-A1 | New piperidinylamino-thieno[2,3-D] pyrimidine compounds | PGXHEALTH, LLC | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280050-A1 | Piperidinylamino-Thieno[2,3-D] Pyrimidine Compounds for Treating Fibrosis | HTR2B, HTR3B, HTR1B | MEN1 4310/4885KMT2A 2743/4885RXFP1 170/4885 |
| US-20050222175-A1 | New piperidinylamino-thieno[2,3-D] pyrimidine compounds | HTR5A, HTR3A, HTR1A | MEN1 2389/4885KMT2A 4258/4885RXFP1 246/4885 |
| US-20100113485-A1 | Piperidinylamino-thieno[2,3-D] Pyrimidine Compounds | HTR2B, HTR3B, HTR1B | MEN1 4118/4885KMT2A 3047/4885RXFP1 357/4885 |
| US-20050222176-A1 | Piperidinylamino-thieno[2,3-D] pyrimidine compounds | HTR2B, HTR3B, HTR1B | MEN1 4118/4885KMT2A 3047/4885RXFP1 357/4885 |
| US-20110082157-A1 | Piperidinylamino-Thieno [2,3-D] Pyrimidine Compounds | HTR5A, HTR3A, HTR1A | MEN1 2784/4885KMT2A 4320/4885RXFP1 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.